

DR. M. SOY PROTEINS LIMITED

Regd. Office: 25/12A Gali No 8 Anandparbat New Rohtak Road, New Delhi-110005

CIN: L01119DL1986PLC023698

E-Mail ID: drmsoy@gmail.com, Ph.:011-28716806

14.09.2017

To

Metropolitan Stock Exchange Limited
(formerly known as MCX stock Exchange Ltd.)
4th Floor, Vibgyor Towers,
Plot No. C-62, G Block, Opp. Trident Hotel,
BandraKurla Complex, Bandra (E),
Mumbai – 400 098

SYMBOL: DRMSOY

Sub: Outcome of the Board Meeting held on 14.09.2017

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, inter alia, has approved the unaudited Results for the Quarter ending 30.06.2017.

We enclose herewith the unaudited financial results of the Company for the quarter ending June 30th, 2017 pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further, please note that the Company has made necessary arrangement to publish the unaudited financial results in the newspaper as required under the SEBI (LORD) Regulations, 2015.

Kindly take the same on your records.

Thanking You,

Yours Faithfully

For Dr. M. Soy Proteins Limited



Managing Director

DIN: 00289179

Name: Prem Prakash Gupta

Address: 18B/1, D.B. Gupta Road, Dev Nagar

Karol Bagh, New Delhi-110005

Independent Auditor's Review Report on Quarterly Standalone Financial Results of Dr M SOY PROTEINS LIMITED pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015

To

The Board of Directors of
Dr M Soy Proteins Limited
New Delhi-110005

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Dr M Soy Proteins Limited ("the Company") for the quarter ended 30 June, 2017 ("the statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and disclosure Requirements) Regulations,2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5,2016. Attention is drawn to the fact that the figures for the corresponding quarter Ended 30 June 2016 including the reconciliation of net profit for the quarter Under Ind-AS of the corresponding quarter with net profit for the quarter Reported under previous GAAP, as reported in these financial results have Been approved by the company's Board of Directors but have not been Subjected to review.

This Statement is the responsibility of the company's Management and has Been approved by the Board of Directors. Our responsibility is to issue a report on these Financial Statement based on our review



We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*," issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to Whether the Statement is free of material misstatement. A review is limited primarily to Inquiries of Company personnel and analytical procedures applied to financial Data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as state above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the applicable Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and principles generally accepted in India, has not disclosed the

information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5,2016, including the manner in which it is to be disclosed, or that it contains any material mis-statement.

For Punit Goel & Company,

Chartered Accountants

(Punit Goel)

Proprietor

521434

Place, New Delhi

Date: 14.09.2017

DR. M. SOY PROTEINS LIMITED

Registered office : 25/12A, GALI NO-8 ,ANANDPARBAT, NEW ROHTAK ROAD, NEW DELHI-110005

CIN: L01119DL1986PLC023698

PH: 011-28716806, Email id: drmsoy@gmail.com

Rs. In lakhs

Statement of Standalone un-audited Financial Results for the Quarter Ended 30/06/2017

Sr. No.	Particular	Quarter Ended	
		30.06.2017	30.06.2016
		(Unaudited)	(Unaudited)
1	Income From Operations		
	Net Sales/ Income from operations	4.97	5.34
	Other Operating Income	0.00	0.00
	Total Income from Operations	4.97	5.34
2	Expenses		
	(a) Cost of materials consumed	0.00	0.00
	(b) Purchase of stock-in-trade	4.51	5.10
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00
	(d) Employee benefits expense	1.53	1.60
	(f) Depreciation and amortisation expense	0.12	0.00
	(g) Other expenses		
	(i) Exise Duty		
	(ii) Power & Fule		
	(iii) Other Expenses	4.31	3.54
	Total expenses	10.47	10.24
3	Profit / (Loss) from Operations before Other Income, Finance Cost, exceptional Items (1-2)	-5.50	-4.90
4	Other Income	11.40	4.03
5	Profit / (Loss) from extraordinary activities before finance Cost & exceptional items (3-4)	5.90	-0.87
6	Finance Cost	0.00	0.00
7	Profit / (Loss) from ordinary activities after finance Cost but before exceptional items (5-6)	5.90	-0.87
8	Exceptional Items	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7-8)	5.90	-0.87
10	Tax Expenses:	0.00	0.00
11	Profit / (Loss) from ordinary activities after tax (9-10)	5.90	-0.87
12	Extraordinary Items	0.00	0.00
13	Net Profit / (Loss) for the period (11+12)	5.90	-0.87
14	Other comprehensive Income(OCI)	0.00	0.00
	A Item that will not be reclassified to profit or loss(net of tax)	0.00	0.00
	B Item that will be reclassified to profit or loss(net of tax)	0.00	0.00
15	Total Comprehensive income for the period(13+14)	5.90	-0.87
16	Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	763.02	763.02
17	Earnings per share (after extraordinary items not annualised)		
	(a) Basic	0.08	-0.01
	(b) Diluted	0.08	-0.01

DR M. SOY PROTEINS LIMITED

Notes:

- 1 Results for the quarter ended 30 June, 2017 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on **14.09.2017**.
2. The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment Rules), 2016 prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1 April, 2017, The Company has for the first time adopted Ind AS with a transition date of 1 April, 2016.
3. The format for above results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated 30 November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5 July, 2016, Ind AS and Schedule III (Division-II) to the Companies Act, 2013 applicable to Companies that are required to comply with Ind AS. Pursuant to this Circular, the above results do not include Ind AS complaint results for the preceding quarter and previous year ended 31 March, 2017 as the same are not mandatory.
4. The statutory Auditors have carried out the "Limited Review" of the results for the quarter ended 30 June, 2017. The Ind AS compliant financial results pertaining to the corresponding quarter Ended 30 June, 2016, have not been subjected to limited review or audit. However, the Management has exercised necessary due diligence to ensure that the financial results provided a True and fair view of its affairs.
5. The Company's Operation predominantly comprises of only one business segment – Income from Trading of Flour (Aatta).
6. Reconciliation between financial results as per previous Indian GAAP and Ind AS for the quarter ended 30 June, 2016 :-

[Rs. In Lacs]			
Sr. No.	Description	Sub Notes	Quarter ended 30 June, 2016
	Net Profit (loss) as per previous Indian GAAP		-0.87
1	Fair Valuation adjustments for financial assets	(i)	0
2	Actuarial loss on employee defined benefits plan recognised in OCI	(ii)	0
3	Other adjustments	(iii)	0
4	Deferred Tax impact on Ind AS adjustments	(iv)	0
	Net Profit (loss) as per Ind AS		-0.87

Sub-Notes :

(i) Under Indian GAAP, deferred taxes are recognised using income statement approach i.e. reflecting the tax effects of timing differences between accounting income and taxable income for the period. The impact of transition adjustments together with Ind AS mandate of using balance sheet approach (against income approach under Indian GAAP) for computation of deferred tax has resulted in consequential impact to statement of Profit and Loss.

Ravi Shrivastava

7. Investors Complaints: Pending at the beginning of Quarter: Nil, Received during Quarter : Nil, Disposed off During Quarter : Nil, Unresolved at the end of Quarter : Nil.

8. Figures of the previous period have been regrouped wherever necessary.

9. The above Standalone Unaudited Financial Results for the quarter ended 30.06.2017 are available On company's web site www.msoyproteins.com and MCX websites www.msei.in.

By and on Behalf of the Board

Place: Delhi
Date:14.09.2017



[PREM PRAKSH]
Managing Director
00289179